Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body (VITASTIQ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03399240|
Recruitment Status : Completed
First Posted : January 16, 2018
Last Update Posted : January 16, 2018
|Condition or disease||Intervention/treatment||Phase|
|No Conditions||Device: Vitasitiq device||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body|
|Actual Study Start Date :||May 17, 2017|
|Actual Primary Completion Date :||November 2, 2017|
|Actual Study Completion Date :||November 2, 2017|
Experimental: Vitastiq device
Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
Device: Vitasitiq device
Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
- Vitastiq device accuracy and performance [ Time Frame: 30 minutes ]Vitastiq accuracy performance is at least 70% meaning that at least 70% of Vitastiq readings for each mineral and vitamin fall within the range of matching blood test results.
- Vitastiq readings method is repeatable [ Time Frame: 30 minutes ]Vitastiq readings method is at least 80% repeatable. It means that at least 80% of Vitastiq readings for each mineral and vitamin performed by investigators and participant in the time frame of 30 minutes are comparable.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03399240
|Adria Lab d.o.o.|
|Ljubljana, Slovenia, 1000|